Kolon Life Science appeals to the Supreme Court for Invossa
By Nho, Byung Chul | translator Kim, Jung-Ju
24.02.28 19:27:55
가나다라
0
Will make efforts to restore scientific value and rectify the legal misunderstandings at the final trial
The appeal is unrelated to the outcome of the administrative proceedings and has no bearing on Kolon TissueGene's Phase III trial in the U.S.
"Will successfully complete trial and bring value."
On the 28th, Kolon Life Sciences decided to appeal to the Supreme Court against the manufacturing and sales license revocation ruling that had been made for its knee osteoarthritis cell gene therapy Invossa-K Inj (“Invossa”).
In its appeal to the court, Kolon Life Sciences explained, "While we respect the court's decision, we will strive to restore the scientific achievements and value of Invossa, the world's first gene therapy for osteoarthritis, by correcting the misunderstandings that arose regarding the product’s legal principles and safety at the appellate court.”
In 2019, Kolon Life Sciences filed an administrative suit to seek the court’s ruling on the illegality and
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)